drugset / Trial / NCT07403721
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
Timeline
- Start
- 2026-04-08
- Primary completion
- 2028-06-28
- Completion
- 2028-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 436 | Unknown | — | — |
Indications
No indication recorded.